A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and oth... von Sinha, Rajni, Kaufman, Jonathan L., Khoury, Hanna Jean, King, Nassoma, Shenoy, Pareen J., Lewis, Carol, Bumpers, Kevin, Hutchison‐Rzepka, Amanda, Tighiouart, Mourad, Heffner, Leonard T., Lechowicz, Mary Jo, Lonial, Sagar, Flowers, Christopher R.

Volltext

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase ch... von SHAH, Neil P, KIM, Dong-Wook, LAMBERT, Alexandre, MATLOUB, Yousif, HOCHHAUS, Andreas, KANTARJIAN, Hagop, ROUSSELOT, Philippe, DORLHIAC LLACER, Pedro Enrique, ENRICH, Alicia, VELA-OJEDA, Jorge, SILVER, Richard T, KHOURY, Hanna Jean, MÜLLER, Martin C

Volltext

Reducing the Risk for Transplantation-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: How Much Progress Has Been Made? von HORAN, John T, LOGAN, Brent R, KHOURY, Hanna Jean, JUCKETT, Mark B, LITZOW, Mark R, MARTINO, Rodrigo, MCCARTHY, Philip L, SMITH, Franklin O, RIZZO, J. Douglas, PASQUINI, Marcelo C, AGOVI-JOHNSON, Manza-A, LAZARUS, Hillard M, BACIGALUPO, Andrea A, BALLEN, Karen K, BREDESON, Christopher N, CARABASI, Matthew H, GUPTA, Vikas, HALE, Gregory A

Volltext

A phase 1 dose‐escalation study of ARRY‐520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias von Khoury, Hanna Jean, Garcia‐Manero, Guillermo, Borthakur, Gautam, Kadia, Tapan, Foudray, Maria Cielo, Arellano, Martha, Langston, Amelia, Bethelmie‐Bryan, Beverly, Rush, Selena, Litwiler, Kevin, Karan, Sharon, Simmons, Heidi, Marcus, Adam I., Ptaszynski, Mieke, Kantarjian, Hagop

Volltext

FGFR3 Activates RSK2 to Mediate Hematopoietic Transformation through Tyrosine Phosphorylation of RSK2 and Activation of the MEK/ERK Pathway von Kang, Sumin, Dong, Shaozhong, Gu, Ting-Lei, Guo, Ailan, Cohen, Michael S., Lonial, Sagar, Khoury, Hanna Jean, Fabbro, Doriano, Gilliland, D. Gary, Bergsagel, P. Leif, Taunton, Jack, Polakiewicz, Roberto D., Chen, Jing

Volltext

Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors von Kong, Jee Hyun, Winton, Elliott F, Heffner, Leonard T, Gaddh, Manila, Hill, Brittany, Neely, Jessica, Hatcher, Angela, Joseph, Meena, Arellano, Martha, El-Rassi, Fuad, Kim, Audrey, Khoury, Jean Hanna, Kota, Vamsi K

Volltext

Dasatinib treatment for Philadelphia chromosome‐positive leukemias von Khoury, Hanna Jean, Guilhot, François, Hughes, Timothy P., Kim, Dong‐Wook, Cortes, Jorge E.

Volltext

Epidermal Growth Factor Stimulates RSK2 Activation through Activation of the MEK/ERK Pathway and Src-dependent Tyrosine Phosphorylation of RSK2 at Tyr-529 von Kang, Sumin, Dong, Shaozhong, Guo, Ailan, Ruan, Hong, Lonial, Sagar, Khoury, Hanna Jean, Gu, Ting-Lei, Chen, Jing

Volltext

14–3-3 integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1–transformed hematopoietic cells von Dong, Shaozhong, Kang, Sumin, Gu, Ting-Lei, Kardar, Sean, Fu, Haian, Lonial, Sagar, Khoury, Hanna Jean, Khuri, Fadlo, Chen, Jing

Volltext

Is the Incidence of Heparin-Induced Thrombocytopenia Affected by the Increased Use of Heparin for VTE Prophylaxis? von Zhou, Amy, MD, Winkler, Anne, MD, Emamifar, Amir, PharmD, Gartland, Bryce, MD, Duncan, Alexander, MD, Antun, Ana, MD, Arellano, Martha, MD, Tindol, G. Allen, MD, Levy, Jerrold H., MD, Bornstein, William A., MD, Horowitz, Ira R., MD, Khoury, Hanna Jean, MD

Volltext

Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease von Khoury, Hanna Jean, Langston, Amelia A., Kota, Vamsi K., Wilkinson, Jennifer A., Pusic, Iskra, Jillella, Anand, Bauer, Stephanie, Kim, Audrey S, Roberts, Danielle, Al-Kadhimi, Zaid, Bodo, Imre, Winton, Elliott, Arellano, Martha, DiPersio, John F.

Volltext

Management of Advanced-Phase Chronic Myeloid Leukemia von DeFilipp, Zachariah, Khoury, Hanna Jean

Volltext

Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1 von Balusu, Ramesh, Fiskus, Warren, Rao, Rekha, Chong, Daniel G., Nalluri, Srilatha, Mudunuru, Uma, Ma, Hongwei, Chen, Lei, Venkannagari, Sreedhar, Ha, Kyungsoo, Abhyankar, Sunil, Williams, Casey, McGuirk, Joseph, Khoury, Hanna Jean, Ustun, Celalettin, Bhalla, Kapil N.

Volltext

Results from REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease von Jagasia, Madan, Perales, Miguel-Angel, Schroeder, Mark A, Ali, Haris, Shah, Nirav N, Chen, Yi-Bin, Arbushites, Michael C., Dawkins, Fitzroy, Tian, Chuan, Khoury, Hanna Jean

Volltext

Sustained Complete Molecular Remission After Discontinuation of Tyrosine Kinase Inhibitors in Blast-Phase Chronic Myeloid Leukemia von Hill, Brittany G, Shen, Ann Qi, El Rassi, Fuad, Khoury, Hanna Jean

Volltext

Updated Product Label Allows Home Administration of Omacetaxine Mepesuccinate von Shen, Ann Q., Munteanu, Mihaela, Khoury, Hanna Jean

Volltext

Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia? von Kong, Jee Hyun, Winton, Elliott F., Heffner, Leonard T., Chen, Zhengjia, Langston, Amelia A., Hill, Brittany, Arellano, Martha, El‐Rassi, Fuad, Kim, Audrey, Jillella, Anand, Kota, Vamsi K., Bodó, Imre, Khoury, Hanna Jean

Volltext

Predicting early blast transformation in chronic‐phase chronic myeloid leukemia: Is immunophenotyping the missing link? von El Rassi, Fuad, Bergsagel, John D., Arellano, Martha, Gaddh, Manila, Jillella, Anand, Kota, Vamsi, Heffner, Leonard T., Winton, Elliott F., Khoury, Hanna Jean

Volltext

Temperature and Humidity Effects on Acute Vaso-Occlusive Pain Episodes in Sickle Cell Disease von El Rassi, Fuad, Randall, Eldrida, Stein, Sidney F., Khoury, Hanna Jean, Eckman, James R., McLemore, Morgan L.

Volltext

Outcomes of Chronic Phase Chronic Myeloid Leukemia Patients Following Tyrosine Kinase Inhibitors Dose-Reductions von Kong, Jee Hyun, Khoury, Hanna Jean, Winton, Elliott F., Heffner, Leonard T., Gaddh, Manila, Arellano, Martha, El-Rassi, Fuad, Kim, Audrey S, Jillella, Anand, Bodó, Imre, Kota, Vamsi

Volltext